Development

Diamyd considering options after Phase III failure for retogatein in type 1 diabetes

Diamyd Medical (Sweden) has terminated the Phase 3 DIAGNODE-3 trial of retogatein (rhGAD65), an antigen-specific immunotherapy for Stage 3 type 1 diabetes,...

Sweden-based Diamyd Medical (STO: DMYD-B) announced the termination of the Phase III DIAGNODE-3 trial for retogatein (rhGAD65), an antigen-specific immunotherapy for Stage 3 type 1 diabetes. The decision followed a pre-planned interim futility analysis that determined the study was unlikely to meet its primary endpoint.

Trial specifics

Retogatein, formulated with alum adjuvant, is designed to induce immune tolerance to glutamic acid decarboxylase 65 (GAD65) and preserve residual beta-cell function in patients carrying the HLA DR3-DQ2 genotype. DIAGNODE-3 was a confirmatory, placebo-controlled Phase IIi trial enrolling patients with recent-onset Stage 3 type 1 diabetes who carried the HLA DR3-DQ2 genotype — a subgroup representing approximately 40% of type 1 diabetes patients in Europe and the United States. The interim analysis drew on data from 174 evaluable participants followed to month 15. The primary objective was preservation of endogenous insulin secretion, measured by C-peptide levels.

The company said the interim results showed no clinically meaningful effect on C-peptide in either the overall population or any pre-specified subgroup. Glycemic data, including HbA1c and Time in Range, were consistent with the C-peptide findings and showed no observable differences between the active and placebo arms. A subsequent review of data derivation, patient randomization, and statistical assumptions identified no factors that altered the interpretation. No new safety signals were identified. Diamyd Medical said it will proceed with full dataset unblinding and a comprehensive analysis to characterize the outcome.

Retogatein had previously generated positive signals in a Phase IIb trial conducted in Europe and in a large-scale meta-analysis, both restricted to the HLA DR3-DQ2 population — the same genetic subgroup enrolled in DIAGNODE-3. Those earlier findings had provided the rationale for advancing to a confirmatory Phase III study. The company picked up US FDA Orphan Drug Designation and Fast Track Designation for retogatein in Stage 3 type 1 diabetes, with additional Fast Track Designation for Stage 1 and 2 disease. A Phase II trial assessing retogatein in pre-symptomatic (Stage 1/2) type 1 diabetics is still listed as recruiting. In addition, Diamyd secured USD 25 million upfront in an equity financing round to support the study just last month.

The AllSci BriefSystematic R&D and deal news. Daily.

What next for Diamyd?

The future of the broader GAD-based immunotherapy program, including any potential development in pre-symptomatic disease stages, is now under reassessment pending the full data analysis, the company said. The DIAGNODE-3 failure leaves Diamyd without a viable late-stage development pathway for retogatein. The company's board has initiated a formal strategic review encompassing external asset acquisition, partnerships, and potential corporate transactions. Diamyd also flagged workforce reductions and cost adjustments. Its wholly owned biomanufacturing facility in Umeå, Sweden — currently undergoing GMP certification for recombinant GAD65 protein production — is being evaluated as a potential standalone contract development and manufacturing operation.

The type 1 diabetes research context

Antigen-specific immunotherapy for type 1 diabetes has a long history of Phase III failures. The immunological heterogeneity of the disease, the narrow window for intervention around diagnosis, and the challenge of translating biomarker signals from smaller genetically enriched cohorts into adequately powered confirmatory trials have each contributed to attrition in this space. The DIAGNODE-3 result is consistent with that pattern: a well-controlled patient population in which the treatment produced no detectable effect on beta-cell preservation, despite prior evidence of activity in the same genetic subgroup.

The company’s DIAGNODE-3 review did not identify trial-execution or statistical issues that changed the interim interpretation, which makes a simple operational explanation for the futility outcome less likely, though full unblinded analysis is still pending. The failure raises questions about whether HLA genotype alone is a sufficient enrichment strategy for antigen-specific immunotherapy in established type 1 diabetes, or whether additional biomarkers of immune activity or residual beta-cell mass are needed to identify a responsive population. The organizational consequences are substantial: Diamyd Medical enters a strategic review as a single-asset company whose lead program has now failed at the pivotal stage, with its primary near-term value residing in manufacturing infrastructure rather than clinical data.


Spot something wrong? Report an issue with this article